ALREX has a low incidence of elevated IOP1†
In clinical studies, patients treated with ALREX presented similar rates of intraocular pressure (IOP) elevation as placebo.1*†
- Incidence of clinically significant increases in IOP (≥10 mm Hg) was 1% with ALREX and 1% with placebo in two 6-week safety and efficacy trials in patients with seasonal allergic conjunctivitis (SAC).
*Study design: Two 6-week, double-masked, placebo-controlled, multicenter environmental studies conducted during pollen season in which patients (n=268) with moderate to severe signs and symptoms of SAC bilaterally received ALREX (0.2%) or placebo QID for 42 days. Primary efficacy variables were bulbar conjunctival injection (signs) and ocular itching (symptoms) resolution at Day 14.
†If ALREX is used for more than 10 days, IOP should be monitored.